This site is intended for a global audience
Contact Us

Medical Education

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest


Narcolepsy (US and Canada Only) 
  • The burden of illness and symptoms associated with Narcolepsy, including cardiometabolic comorbidities and lifelong management of disease
  • Treatment impact on Narcolepsy and associated comorbidities
  • The potential impact of excessive sodium intake on health and relevance of this risk in Narcolepsy patients (US and Canada Only)
  • Screening and diagnostic challenges of Narcolepsy
  • The impact of delayed diagnosis of Narcolepsy
Idiopathic Hypersomnia (US and Canada Only)  
  • Screening, diagnosis, and management of Idiopathic Hypersomnia
  • Differentiation of Idiopathic Hypersomnia from other causes of EDS
  • Symptoms associated with Idiopathic Hypersomnia and the impact of treatment, including efficacy and safety considerations
  • The burden of illness associated with Idiopathic Hypersomnia, including comorbidities
  • Validated measures for clinical practice assessment of changes in the severity of Idiopathic Hypersomnia
  • The potential impact of excessive sodium intake on health and specific relevance of this risk in Idiopathic Hypersomnia patients
  • Identification, diagnosis and optimal seizure management of Lennox-Gastaut 
    Syndrome (LGS), Dravet Syndrome (DS) or Tuberous Sclerosis Complex (TSC)
  • Management of patient transition from pediatric to adult practices
  • Management of patients with rare developmental and epileptic encephalopathies 
    (DEEs) (e.g., LGS, DS, and TSC) beyond seizures
  • Early epilepsy treatment and improvement of long-term outcomes

Cannabinoid Science 

  • Pre-clinical and clinical research on cannabinoid-based products and medicines including:
    • Systemic reviews
    • Meta analyses
    • Patient case studies
  • Evaluation of differences in evidence/data presented for cannabinoid-based products submitted for regulatory approval (including, for example FDA, EMA, MHRA, PMDA) including evaluations regarding:
    • Clinical trial evidence
    • Established and unknown risks and safety profiles associated with different cannabinoid-based products and medicines
  • Science of cannabinoids (including but not limited to):
    • Sources of cannabinoids (eg phytocannabinoids, endocannabinoids, synthetic cannabinoids)
    • Endocannabinoid system
    • Cannabis plant, phytocannabinoids and active/inactive metabolites
    • Pharmacology


Acute Myeloid Leukemia (AML) 
  • The role of intensive chemotherapy in the treatment of secondary AML
  • Identification and timely, actionable diagnosis of high-risk AML subsets (e.g., AML-MRC, tAML)
  • Different technologies for the delivery of secondary AML treatments
    • Treatment of secondary AML to include:
      • Efficacy
      • Safety
      • Impact on quality of life
      • Depth of response, real world data and long-term outcomes
  • Appropriate management of secondary AML patients in the in-patient and out-patient setting
  • The AML treatment paradigm (e.g., induction, consolidation, combination therapy, maintenance therapy) and patient management
  • Clinical and economic burden of secondary AML
Endothelial Related Complications 
  • Recognition, incidence, risk factors, diagnosis and early intervention of VOD/SOS including in the non-transplant setting
  • VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
  • Pathophysiology, progressive nature and life-threatening complications of advanced VOD/SOS and other endothelial related complications
  • Efficacy, safety and mechanism of action of current therapies and patient management for the treatment of VOD/SOS
  • Clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage
  • Efficacy and safety of current therapies and patient management for COVID-19 related ARDS and other endotheliitis
Small Cell Lung Cancer (SCLC) 
  • Treatment options in second-line therapy for small cell lung cancer (SCLC)
  • Current considerations for SCLC therapies including:
    • Efficacy
    • Safety
    • Mechanism of Action
  • Patient management and safety profiles of SCLC second-line therapies
Acute Lymphoblastic Leukemia (ALL) 
  • The biology of immune response, differentiation and management of asparaginase hypersensitivity reaction vs. infusion reaction and the impact and burden on safety and efficacy
  • The importance of completing treatment and potential safety or other concerns associated with current clinical mitigation strategies for hypersensitivity reactions
  • Recognition and management of asparaginase toxicities in the adult/young adult population
  • Management of pediatric and adult/young adult ALL/LBL with asparaginase (e.g., monitoring, PK, safety, clinical value)
  • Pediatric inspired protocols in the adult/young adult population
  • The efficacy and clinical benefits of new asparaginase formulation in ALL/LBL
  • Asparaginase therapies and combinations beyond ALL/LBL

View our current requests for application.

Eligible educational grant applicants include the following (not an exhaustive list):

  • Medical Schools
  • Medical Associations/Medical Societies
  • Hospitals/Medical Centers
  • Medical Education Providers

This system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities.

In Europe & International (EUR/INT) the system is also accepting requests for medical grants as allowed by local regulations.

The following grant requests are not covered by the educational grant request process: requests for funding educational activities that are promotional in nature (e.g., brand-specific promotional speaker activities); requests for funding activities related to promotion of a commercial product (e.g., commercial exhibits); and operational funding for patient advocacy organizations.

How to Apply

  • Grant requests should be submitted using the Jazz Pharmaceuticals Request Management System.
  • All grant requests should be received by Jazz in complete form at least 60 days prior to the commencement of the educational activity for consideration.
  • The system will guide applicants through the process of determining the request type and the required documents for each request.
  • Jazz Pharmaceuticals does not control or influence the content of programs or the selection of speakers, authors, or faculty planners.
  • All decisions regarding support are at the discretion of Jazz and will be communicated by email.
  • Submission of a request does not guarantee support.
  • For more information, or for questions regarding the status of a grant request, please email